Objective: To correlate Multi-spectral Digital Skin Lesion Analysis classifier scores with histopathological severity of pigmented lesions and clinical features of melanoma. the CS (Table 1). The model demonstrated that an increase in CS of 1 1 TAE684 increased the odds ratio of being melanoma/high-grade dysplastic lesion by 1.66 ((n=57) was 3.9 versus 3.1 (n=70) for invasive melanomas, although this difference was not statistically significant. This finding suggests that melanoma may contain similar morphologic characteristics to the superficial component of invasive melanoma. The MSDSLA CS also correlated with level of morphologic disorganization. Mean CSs were computed for six histological severity levels of lesions: melanomas, high grade lesions (high grade DN, atypical melanocytic proliferation/hyperplasia), low grade DN, non-DN (intradermal nevi, Spitz nevi and junctional nevi), nonmelanoma skin cancers, and other non-nevus benign lesions. TAE684 Of the 15 possible pair wise comparisons of the six histological variants, six statistically significant comparisons were evident using Welchs t-test (Table 2). Data also revealed a direct correlation (Pearson coefficient 0.32, p<0.0001) between CS and the number of ABCDEPRU characteristics (Table 3). TABLE 2 Comparison of mean CSs between lesion types TABLE 3 CS by number of clinical/historical characteristics CONCLUSION This retrospective analysis sought to determine how the level of morphologic disorganization objectively measured by MSDSLA relates to the clinically and histologically subjective features of suspicious pigmented lesions. Higher CSs were significantly associated with more advanced histopathology. Despite the discordance that DDR1 can exist among dermatopathologists when reviewing the same pigmented skin lesion,6 a significant correlation with the severity of the subjective histological description and the objectively generated MSDSLA CS was found. In addition, CS was shown to directly correlate with the number of ABCDEPRU characteristics of melanoma clinically present in the studied lesions. MSDSLA has been shown to improve biopsy accuracy of suspicious pigmented lesions while reducing the number of unnecessary biopsies.4,5,7-9 This study demonstrates that the algorithms used to objectively generate the CS by MSDSLA correlate well with the subjective clinical and histological features that are typically used to assess the likelihood that a pigmented lesion might be melanoma. Footnotes DISCLOSURE:Dr. Winkelmanns fellowship is partially funded by MELA Sciences Inc. Drs. Rigel, Ferris, and Cockerell serve as consultants for MELA Sciences Inc. Dr. Sober is a former consultant for MELA Sciences Inc. Ms. Tucker is an employee of MELA Sciences Inc. REFERENCES 1. [March 9, 2015]. http://www.who.int/uv/health/uv_health2/en/index1.html Health Effects of UV Radiation. Ultraviolet radiation and the INTERSUN Programme. 2015. World Health Organization. Available at: 2. [March 9, 2015.]. http://www.cancer.orgacs/groups/content/@epidemiologysurveil ance/documents/document/acspc-031941.pdf American Cancer Society Cancer Facts and Figures. Available at: 3. Gutkowicz-Krusin D, Elbaum M, Jacobs A, et al. Precision of automatic measurements of pigmented skin lesion parameters with a MelaFind multispectral digital dermoscope. Melanoma Res. 2000;10(6):563C570-E7. [PubMed] 4. Rigel DS, Roy M, Yoo J, et al. Impact of guidance from a computer-aided multispectral digital skin lesion analysis device TAE684 on decision to biopsy lesions clinically suggestive of melanoma. Arch Dermatol. 2012;148(4):541C543. [PubMed] 5. Monheit G, Cognetta AB, Ferris L, et al. The performance of MelaFind: a prospective multicenter study. Arch Dermatol. 2010;147(2):188C194. [PubMed] 6. Braun RP, Gutkowicz-Krusin D, Rabinovitz H, et al. Agreement of dermatopathologists in the evaluation of clinically difficult melanocytic lesions: how golden is the gold standard? Dermatology. 2012;224(1):51C58. [PubMed] 7. Yoo J, Roy M, White R, Rigel DS. Impact of guidance from a computer-aided multispectral digital skin lesion analysis device on dermatology residents decision to biopsy lesions clinically suggestive of melanoma. J Am Acad Dermatol. 2013;68(4):s1CAB152.. [PubMed] 8. Hauschild A, Chen SC, Weichenthal M, et al. To excise or not: impact of MelaFind on German dermatologists decisions to biopsy atypical lesions. J Dtsch Dermatol Ges. 2014;12(7):606C614. [PubMed] 9. Wells R, Gutkowicz-Krusin D, Veledar E, et al. Comparison of diagnostic and management sensitivity to melanoma between dermatologists and MelaFind: a pilot study. Arch Dermatol. 2012;148(9):1083C1084. [PubMed].